Global Cord Blood Stock Forecast, Price & News

Global Cord Blood (NYSE:CO) Frequently Asked Questions

How has Global Cord Blood's stock price been impacted by COVID-19?

Global Cord Blood's stock was trading at $4.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CO shares have decreased by 2.0% and is now trading at $3.99.
View which stocks have been most impacted by COVID-19.

When is Global Cord Blood's next earnings date?

Global Cord Blood is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Global Cord Blood.

How were Global Cord Blood's earnings last quarter?

Global Cord Blood Co. (NYSE:CO) released its earnings results on Tuesday, June, 26th. The medical research company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.09. The medical research company had revenue of $37.14 million for the quarter. Global Cord Blood had a net margin of 41.45% and a trailing twelve-month return on equity of 11.36%.
View Global Cord Blood's earnings history.

Who are Global Cord Blood's key executives?

Global Cord Blood's management team includes the following people:

• Ting Zheng, Chairman & Chief Executive Officer
• Bing Chuen Chen, Chief Financial Officer & Director
• Xin Xu, Chief Technology Officer
• Rui Arashiyama, CEO-Guangdong & Zhejiang Divisions

Who are some of Global Cord Blood's key competitors?

Some companies that are related to Global Cord Blood include Tivity Health (TVTY), Convey Holding Parent (CNVY), HemaCare (HEMA), Quipt Home Medical (QIPT), SOC Telemed (TLMD), Viemed Healthcare (VMD), Viemed Healthcare (VMD), Ontrak (OTRK), Cryo-Cell International (CCEL), Greenbrook TMS (GBNH), Marpai (MRAI), Caladrius Biosciences (CLBS), Curative Biotechnology (CUBT), Baudax Bio (BXRX) and Curative Biotechnology (CTYX).
View all of CO's competitors.

What other stocks do shareholders of Global Cord Blood own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Cord Blood investors own include AbbVie (ABBV), Fate Therapeutics (FATE), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Spero Therapeutics (SPRO), Vertex Pharmaceuticals (VRTX), Enphase Energy (ENPH), Galectin Therapeutics (GALT), Intel (INTC) and Marvell Technology (MRVL).

What is Global Cord Blood's stock symbol?

Global Cord Blood trades on the New York Stock Exchange (NYSE) under the ticker symbol "CO."

Who are Global Cord Blood's major shareholders?

Global Cord Blood's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.52%), Man Group plc (1.46%), BlueCrest Capital Management Ltd (1.20%), Barclays PLC (0.17%), Arrowstreet Capital Limited Partnership (0.16%) and Verition Fund Management LLC (0.07%).
View institutional ownership trends for Global Cord Blood.

Which major investors are selling Global Cord Blood stock?

CO stock was sold by a variety of institutional investors in the last quarter, including BlueCrest Capital Management Ltd, Renaissance Technologies LLC, Citadel Advisors LLC, and Millennium Management LLC.
View insider buying and selling activity for Global Cord Blood or view top insider-selling stocks.

Which major investors are buying Global Cord Blood stock?

CO stock was bought by a variety of institutional investors in the last quarter, including Verition Fund Management LLC, Arrowstreet Capital Limited Partnership, Barclays PLC, Man Group plc, Two Sigma Advisers LP, and American Century Companies Inc..
View insider buying and selling activity for Global Cord Blood or or view top insider-buying stocks.

How do I buy shares of Global Cord Blood?

Shares of CO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global Cord Blood's stock price today?

One share of CO stock can currently be purchased for approximately $3.99.

How much money does Global Cord Blood make?

Global Cord Blood has a market capitalization of $484.99 million and generates $176.99 million in revenue each year. The medical research company earns $77.57 million in net income (profit) each year or $0.64 on an earnings per share basis.

How many employees does Global Cord Blood have?

Global Cord Blood employs 1,260 workers across the globe.

What is Global Cord Blood's official website?

The official website for Global Cord Blood is www.globalcordbloodcorp.com.

Where are Global Cord Blood's headquarters?

Global Cord Blood is headquartered at 48 FL. BANK OF CHINA TOWER 1 GARDEN ROAD, HONG KONG K3, .

How can I contact Global Cord Blood?

Global Cord Blood's mailing address is 48 FL. BANK OF CHINA TOWER 1 GARDEN ROAD, HONG KONG K3, . The medical research company can be reached via phone at (523) 605-8180, via email at [email protected], or via fax at 852-3605-8181.